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Abstract
MicroRNAs play key roles in tumor metastasis. Here, we describe the regulation and function of miR-218 in gastric cancer
(GC) metastasis. miR-218 expression is decreased along with the expression of one of its host genes, Slit3 in metastatic GC.
However, Robo1, one of several Slit receptors, is negatively regulated by miR-218, thus establishing a negative feedback
loop. Decreased miR-218 levels eliminate Robo1 repression, which activates the Slit-Robo1 pathway through the interaction
between Robo1 and Slit2, thus triggering tumor metastasis. The restoration of miR-218 suppresses Robo1 expression and
inhibits tumor cell invasion and metastasis in vitro and in vivo. Taken together, our results describe a Slit-miR-218-Robo1
regulatory circuit whose disruption may contribute to GC metastasis. Targeting miR-218 may provide a strategy for blocking
tumor metastasis.
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Introduction
Advances in diagnostic and therapeutic approaches have led to
excellent expectations for long-term survival for early gastric
cancer (GC). However, the prognosis for advanced GC with
extensive invasion and metastasis remains poor [1]. In order to
metastasize, tumor cells must pass through a series of sequential
and selective events, including detachment, migration, local
invasion, angiogenesis, intravasation, survival in the circulatory
system, extravasation, and regrowth in different organs. In the
metastatic cascade, invasion of GC into the surrounding tissue is a
crucial early step [2–4]. However, the mechanisms of invasion
have not yet been fully elucidated.
A large number of microribonucleic acids (microRNAs or
miRNAs) have been recently implicated in cancer metastasis [5],
including miR-10b, miR-21, miR-126, miR-335, miR-373, miR-
146, miR-520c, and miR-205 in breast cancer [6–11]; miR-224
and miR-21 in prostate cancer [12,13]; miR-29c in nasopharyn-
geal carcinomas [14]; miR-10a, miR-222, miR-125b, miR-7, and
miR-452 in urothelial carcinomas [15]; miR-182 in melanoma
[16]; miR-92b and miR-9/9* in brain tumors [17]; and miR-21 in
colorectal cancer [18]. However, very few miRNAs known to be
involved in GC metastasis have been reported. miRNAs are
naturally occurring, short, non-coding RNA molecules that
negatively regulate gene expression [19]. In mammals, mature
miRNAs are generated from pri-miRNAs and pre-miRNAs via
sequential processing by Drosha and Dicer and are found in many
organisms. They consist of 21–24 nucleotides, integrate into RNA-
inducing silencing complexes, and pair with the 39 untranslated
regions (39-UTR) of specific target messenger RNAs (mRNAs) to
suppress translation or induce degradation of the target mRNAs
[20]. Emerging evidence has revealed that miRNAs play key roles
in various biological processes, including cell differentiation,
proliferation, apoptosis, stress resistance, fat metabolism, tumor-
igenesis, and metastasis [21–23]. A better understanding of the
changes in miRNA expression during GC invasion may lead to a
better understanding of GC development, as well as possible
improvements in the diagnosis and treatment of advanced GC.
In the present study, we established high (MKN28-M and
SGC7901-M) and low invasive cell sublines (MKN28-NM and
SGC7901-NM) using a repetitive transwell assay in vitro. We then
examined the global miRNA expression profile in each cell subline
using a miRNA microarray to identify differentially expressed
miRNAs related to human GC invasion. In total, 45 miRNAs
were shown to be differentially expressed in invasive vs. non-
invasive GC cells. Among these, miR-218, a significantly
downregulated miRNA in highly invasive cells, was shown to be
closely correlated with GC tumorigenesis and metastasis in
patients. More recently, a decrease in miR-218 has been reported
in several kinds of solid tumors, including prostate cancer, GC,
lung cancer, and cervical carcinoma [24–27], but this decrease in
miRNA-218 was simply screened out as being one of the dozens of
potential miRNAs of interest in the cancers described above. No
further studies have been performed to assess the significance of
miR-218 in tumor metastasis. Here, we have found that decreased
miR-218 expression was correlated with advanced clinical stage,
lymph node metastasis, and poor prognosis in patients, and re-
expression of miR-218 in metastatic cells was able to inhibit
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vivo. Using a bioinformatics search for miR-218 targets, we
pinpointed the receptor Robo1 as miR-218’s functional target,
and we confirmed that the interaction between miR-218 and
Robo1 was crucial to GC cell motility by demonstrating that there
was an inverse correlation between miR-218 and Robo1 in GC
cell lines as well as in GC patients. Furthermore, we discovered an
intriguing negative feedback loop involving Slit, miR-218, and
Robo1, in which miR-218 can be derived from either of two genes
located in the introns of two distinct members of the Slit protein
family. In addition, members of this family are ligands of the
Robo1 receptor. We demonstrated that expression of the two
miRNA precursor genes (miR-218-1 and miR-218-2) correlated
with expression of the host genes (Slit2 and Slit3, respectively) and
that the mature miR-218 was mainly derived from the miR-218-2
precursor, with a concomitant reduction of host Slit3 but not of
Slit2 in metastatic GC cells. Thus, upregulation of Robo1 in
response to the decrease in miR-218 induced a reactive
upregulation of the Slit-Robo1 pathway through its interaction
with Slit2, thus facilitating tumor cell invasion and metastasis. Our
findings not only provide new insights into the metastatic
mechanisms in GC, but they also revealed a novel regulatory
mechanism of receptor signaling.
Results
Establishment and characterization of cell sublines with
different invasive and metastatic potentials
To establish the GC metastasis models, we created invasive and
non-invasive cell sublines from the human GC cell lines SGC7901
and MKN28 using the repeated transwell approach (Figure 1A,
see Materials and Methods). Briefly, a repetitive invasion assay was
performed, and those cells that failed to invade the membranes
and cells that had the ability to migrate through the collagen-
coated membrane in all selection rounds were separated. After ten
rounds of selection, we obtained invasive (MKN28-M and
SGC7901-M) and non-invasive cell sublines (MKN28-NM and
SGC7901-NM). The metastatic properties of each cell subline
were then characterized in vitro and in vivo. As shown in Figure 1B
and 1C, migration ability of MKN28-M cells was approximately
4-fold greater than that of MKN28-NM cells. Likewise, the
invasive potential was about 5-fold greater for MKN28-M cells as
compared to MKN28-NM cells. In the in vivo studies, tumor cell
metastasis was observed in nude mice. As shown in Figure 1D and
1E, almost no metastatic GC cells were detected in the lungs or
livers of nude mice at 10 weeks after injection of MKN28-NM
cells, whereas most of the mice injected with MKN28-M cells
displayed obvious lung or liver metastases. Similar results were
observed for SGC7901-M and SGC7901-NM cells (data not
shown). No significant differences in cell proliferation or cell-cycle
distribution were observed among these cell sublines (Text S1,
Figures S1 and S2).
Identification of metastasis-related miRNAs by array-
based hybridization
To identify miRNAs potentially involved in GC invasion, we
examined global miRNA expression in each cell subline using the
microRNA array (v.10.0, Exiqon, Vedbaek, Denmark), which
consists of 847 capture probes for mature human miRNAs. The
microarray results revealed that the expression of 124 miRNAs
significantly differed between the highly invasive variant MKN28-
M and the non-invasive cell subline MKN28-NM. Of these, 83
were upregulated and 41 were downregulated. Compared with
SGC7901-NM, 62 miRNAs were differentially expressed in the
SGC7901-M cell subline, including 47 downregulated and 15
upregulated miRNAs. In total, 11 miRNAs were found to be
upregulated and 34 miRNAs were downregulated in both
MKN28-M and SGC7901-M cells compared with those in the
corresponding non-invasive sublines (Table S1).
Of the 45 differentially regulated miRNAs, miR-218 was one of
those that displayed significantly differential expression. miR-218
has been reported to be downregulated in cervical cancer [25],
Figure 1. The metastatic characteristics of each cell subline. (A)
General scheme of the establishment of invasive and non-invasive cell
sublines derived from human GC cell lines. (B,C) In vitro migration and
invasion activity of each cell subline. Migration and invasion activities
were measured in vitro with transwell chambers, as described in
Materials and Methods. Photos are representative fields of invasive cells
on the membrane. Magnification, 100x. Bar graphs represent the
average number of cells on the underside of the membrane 6 SE.
** P,0.01 as compared with non-invasive cells, analyzed by t-test.
(D and E) Metastasis potential of each cell subline in vivo (n=10). (D)
The incidence of metastasis in mice that received intravenous tail
injections of each selected cell subline. (E) H&E staining of lungs and
livers isolated from mice that received intravenous tail injections of
MKN28-NM and MKN28-M cells, respectively. Magnification, 100x.
doi:10.1371/journal.pgen.1000879.g001
Author Summary
MicroRNAs have been identified as playing important roles
in tumor metastasis, but their impact on GC metastasis has
been poorly explored. We have discovered miR-218, which
functions as a suppressor of tumor metastasis and is
correlated with clinical stage, lymph node metastasis, and
prognosis in patients with GC. Our results show that miR-
218 is part of a regulatory circuit involving the Slit-Robo1
pathway. In metastatic tumor cells, miR-218 was sup-
pressed along with Slit3, one of its host genes. Meanwhile,
Robo1, one of several Slit receptors, is upregulated in
response to the decrease in miR-218, which in turn
induced a reactive upregulation of the Slit-Robo1 pathway
through an interaction with Slit2, thus facilitating tumor
cell migration and invasion. Such findings not only provide
new insights into the metastatic mechanisms in GC but
also provide evidence for a novel miRNA–mediated
regulatory mode of receptor signaling.
MiR-218 Inhibits Invasion and Metastasis
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possible involvement in both oncogenic transformation and tumor
metastasis. However, miRNA-218 was only one of the many
potential miRNAs of interest in cancers. In this work, miR-218 has
been investigated in much greater detail. To validate the
microarray results, we assessed miR-218 expression in the GC
cell sublines previously mentioned and in the immortal gastric
epithelial cell line GES using qRT–PCR [29]. miR-218 expression
was significantly decreased in MKN28-M and SGC7901-M cells
and was lower in all four GC cell sublines compared to
immortalized human gastric epithelial GES cells (Figure 2A).
Furthermore, we compared miR-218 expression in the primary
GC tumor vs. the metastatic lymph nodes in 10 patients with stage
III/IV GC using qRT–PCR. As shown in Figure 2B, mature miR-
218 levels were significantly decreased in 7 out of 10 metastatic
lymph nodes, indicating that miR-218 may play a causal role in
GC metastasis.
Decreased miR-218 expression in GC was associated with
advanced clinical stage, lymph node metastasis, and
poor patient prognosis
To determine the potential clinicopathological implications of
altered miR-218 expression, we investigated the expression levels
of miR-218 in 40 GC tissues (T) and non-tumor mucosa (N) by
qRT–PCR. The term -DCt was used to describe the expression
level of miR-218. Consistent with the above data, the results
verified that the miR-218 expression level in GC (-13.8160.15,
mean 6 SE) tissues was significantly lower than that in non-
neoplastic mucosa (-11.6260.15, mean 6 SE) (P,0.0001,
t=10.62, paired t-test) (Figure 3A). Correlations between the
miR-218 expression level and clinicopathologic characteristics of
GC are summarized in Table 1. Statistically significant associa-
tions between the miR-218 expression level and clinical stage and
between the miR-218 expression level and GC metastasis were
observed in this study. The median expression of miR-218 was
214.2560.17 in the 22 cases with advanced stage (stage III and
IV) disease, whereas the median expression was 213.2760.20
(P=0.0010, Mann-Whitney test) in the 18 cases with early-stage
(stages I and II) disease. In the 29 cases of GC with lymph node
metastasis, the median expression of miR-218 was 214.0960.16,
which was significantly lower than the median expression
(213.0760.24) in the 11 non-metastatic GC cases (P=0.0036).
The expression of miR-218 in GC patients did not correlate with
age, gender, tumor size, or cell differentiation. Moreover, we
examined whether the level of miR-218 expression was associated
with survival in patients with GC. Patients were subsequently
divided into low expression (n=20) and high expression groups
(n=20) based on miR-218 levels greater or less than the mean
(213.81) (Figure 3B). Kaplan–Meier survival analyses revealed
that patients whose primary tumors displayed low expression of
Figure 2. Validation of miR-218 expression in metastatic GC
cells. The expression of miR-218 was investigated by qRT-PCR. (A) Each
bar represents the relative fold change compared to GES cell lines. (B)
Bars represent relative fold changes between primary GC and
metastatic lymph nodes from the same patient. Each sample was
analyzed in triplicate and was normalized to U6. Fold change was
calculated by 2
2DDCt. The results were consistent with the microarray
data.
doi:10.1371/journal.pgen.1000879.g002
Figure 3. miR-218 expression in clinical GC specimens. (A) miR-
218 was differentially expressed between GC and the corresponding
non-neoplastic mucosa (N). The term -DCt was used to describe the
expression level of miR-218 (2DCt=CtU62CtmiR-218). A significant
difference was detected in the mean value of miR-218 expression
between these two groups (P,0.0001, t=10.62, paired t-test). (B) The
same GC samples as in (A) were divided into two groups according to
the mean expression of miR-218 (mean, 213.81). Cases with levels of
miR-218 below the mean were miR-218 low expressers (n=20), and
those with levels of miR-218 above the mean were miR-218 high
expressers (n=20). (C) Kaplan–Meier survival curve and log-rank test for
GC patients between high and low miR-218 expressers. miR-218
expression demonstrated a significant relationship with patient survival
(log-rank, P=0.0012).
doi:10.1371/journal.pgen.1000879.g003
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survival rate of patients with low miR-218 expression was 30%,
which was significantly lower than the survival rate in patients with
high miR-218 expression (65%; P=0.0012, log-rank test;
Figure 3C).
Ectopic expression of miR-218 inhibited tumor cell
invasion and metastasis in vitro and in vivo
To study the role of miR-218 in GC metastasis, MKN28-M
cells were transfected with pGenesil-1-miR-218 or a control vector
expressing a nonspecific miRNA, cel-miR-67, using Lipofectamine
2000 (Invitrogen, Carlsbad, CA, USA). The cells were then
selected with 400 mg/L G418 to generate MKN28-M-miR-218
and MKN28-M-miR-control stable cells. We found that ectopic
expression of miR-218 resulted in an approximately three-fold
reduction in migration and invasiveness. To determine whether
the loss of miR-218 would promote the migration or invasion of
cancer cells, we silenced miR-218 with an antisense oligonucle-
otide inhibitor in the MKN28-NM cell line, resulting in a three- to
four-fold increase in cell migration and invasiveness (Figure 4A
and 4B). To test if inhibition of tumor invasion by miR-218 is
caused by impairing the invasive ability of tumor cells, we
excluded the effect of miR-218 on the proliferation and cell cycle
distribution of gastric cancer cells. Over-expression of miR-218
did not affect the proliferation and the cell cycle distribution of
MKN28-M cells in vitro (Figure S5A and S5D). To further
investigate the inhibition of in vivo tumor metastasis by miR-218,
we implanted MKN28-M-miR-218 cells that were stably express-
ing miR-218 or control cells into nude mice through the lateral tail
vein. Lung and liver metastasis of GC was apparent in mice
injected with MKN28-M-miR-control cells. In contrast, few
metastatic tumors were detected in mice injected with MKN28-
M-miR-218 cells (Figure 4C). Furthermore, we simultaneously
observed the growth of the primary tumors and the incidence of
distant metastasis in the nude mice injected subcutaneously with
MKN28-M-miR-218 cells or control cells. The results showed
lung or liver metastasis was apparent in 3 out of 10 mice injected
with MKN28-M-miR-control cells; in stark contrast, no metastasis
were found in mice injected with MKN28-M-miR-218 cells
(Figure S5E). These results are consistent with data obtained from
tail vein assays that assess cancer metastasis and indicate that miR-
218 has the ability to suppress metastasis without affecting cell
proliferation.
Robo1 was a direct functional target of miR-218 in GC
metastasis
To assess how a low level of miR-218 expression contributes to
the invasion and metastasis of GC, we searched for the potential
Table 1. The relationship between clinicopathological
parameters and miR-218 expression in primary gastric
adenocarcinoma.
Variable
Number
of cases %
Median
expression of
miR-218(range)
P-
value
Age (years)
$60 16 40% 213.8360.22 0.85
,60 24 60% 213.7960.21
Gender
Male 30 75% 213.8660.16 0.43
Female 10 25% 213.6660.38
Tumor size
$52 6 6 5 % 213.9160.20 0.36
,51 4 3 5 % 213.6260.22
Degree of
differentiation
well and moderately
differentiated
18 45% 213.7760.23 0.7649
poorly differentiated 22 55% 213.8460.20
TNM stage
Stage I/II 18 45% 213.2760.20 0.0010
*
Stage III/IV 22 55% 214.2560.17
Lymph node status
Metastasis 29 72.5% 214.0960.16 0.0036
*
No metastasis 11 27.5% 213.0760.24
doi:10.1371/journal.pgen.1000879.t001 Figure 4. miR-218 suppressed tumor cell invasion and metas-
tasis. (A) qRT–PCR analysis of miR-218 in MKN28-M cells transfected
with the miR-218-expression vector or the miR-control vector and
MKN28-NM cells transfected with anti-miR-218 or a negative control. (B)
Cell invasion assay. (B1) Average number of invasive cells from three
independent experiments 6 SE. * P,0.05. (B2) Representative fields of
invasive cells on the membrane. (C) In vivo metastasis assay. MKN28-M
cells were transfected with the miR-218-expression vector or the miR-
control vector and injected into nude mice via the tail vein, as described
in Materials and Methods. Animals were killed 10 weeks after injection.
(C1) Incidence of metastasis in mice. (C2) Representative H&E staining of
lungs and livers isolated from mice that received injections of MKN28-M-
miR-control or MKN28-M-miR-218 cells.
doi:10.1371/journal.pgen.1000879.g004
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miRanda, PicTar, and TargetScan. Although hundreds of
different targets were predicted, those genes involved in migration
or invasion may be the relevant targets with respect to the
biological functions of miR-218. We then performed a functional
classification of the predicted targets using the DAVID program
(http://david.abcc.ncifcrf.gov/). Of these genes, Robo1 is regard-
ed as a proto-oncogene and harbors migration-promoting activity
[30–35]. Mertsch et al. demonstrated that Robo1 facilitates glioma
cell migration mediated by Slit2 [36]. Schmid et al. found that
breast tumor cell migration is induced by the Slit2-Robo1
interaction in vitro [37]. These findings suggest that Robo1 may
be a target for miR-218. To further test our hypothesis, we
analyzed the expression of miR-218 and Robo1 in GES and in
non-invasive (MKN28-NM and SGC7901-NM) and invasive
(MKN28-M and SGC7901-M) GC cells. The results showed a
negative correlation between the levels of miR-218 and Robo1
mRNA in these cells (Figure S3A). Furthermore, we observed that
Robo1 mRNA (Figure S3B) and protein (Figure 5B2) levels were
decreased when miR-218 was expressed by pGenesil-1-miR-218
in MKN28-M cells (Figure 5B1). The reverse was observed for
Robo1 expression when miR-218 was knocked down in MKN28-
NM cells (Figure 5C1 and Figure 5C2). The inverse relationship
between miR-218 and Robo1 expression was further confirmed by
immunohistochemistry (Text S1) in 40 cases of gastric cancer, in
matched adjacent normal tissues that were also used in
clinicopathological studies, and in 29 matched metastases. The
results show that Robo1 was upregulated in GC, especially in
metastatic GC (Figure S4), in which miR-218 has a relatively low
expression.
To obtain further direct evidence that Robo1 is a target of miR-
218, we investigated the binding site of miR-218 in the 39-UTR of
Robo1 mRNA (Figure 5A). We constructed a luciferase reporter
(Luc-Robo1) in which the nucleotides of the Robo1 39-UTR
complementary to miR-218 (nt 971–978) were inserted into the
pMIR-REPORT miRNA expression reporter vector [38]. Corre-
spondingly, we also generated both a mutant reporter (Luc-
Robo1-mu), in which the first six nucleotides in the miR-218 seed-
region complementary sites were deleted, and a control reporter,
which contained a non-related fragment of cDNA (Luc-Ctrl). miR-
218-expression plasmids were co-transfected with Luc-Robo1,
Luc-Robo1-mu, or Luc-Ctrl into MKN28-M cells. The assays
showed that the luciferase activity in the Luc-Robo1-transfected
cells was significantly decreased compared to the luciferase activity
in the mutant and negative control cells (P,0.05), suggesting that
miR-218 reduced the luciferase activity of Luc-Robo1 but had no
effect on Luc-Robo1-mu (Figure 5D). Therefore, we concluded
that the inserted fragment of Robo1 (nt 971–978) was the target of
miR-218.
Robo1 has been shown to be over-expressed in cancer cells and
is known to promote tumor angiogenesis and metastasis via an
interaction with Slit [39,40]. To test whether Robo1 is functionally
regulated by miR-218, we generated a Robo1 expression construct
containing only a fragment of the predicted miR-218 binding site
and Robo1 mutant expression vector entirely lacking the 39-UTR.
We also made the Robo1 siRNA. MKN28-M-miR-218 cells,
which stably expressed miR-218 ectopically, were transiently
transfected with the Robo1 construct or the mutant construct (with
no miR-218 binding site), and MKN28-M cells were transfected
with Robo1 siRNA or a negative control siRNA. MKN28-M-
miR-218 cells transfected with the Robo1 mutant construct
showed a 3.8-fold increase in invasion ability compared to cells
transfected with the Robo1 construct. These results indicate that
introduction of mutant Robo1 cDNA that lacked the miR-218
binding site into the miR-218-overexpressing cells reversed the
effect of miR-218-mediated suppression of cell invasion. However,
the effect of Robo1 was repressed by miR-218 in the presence of
the Robo1 39-UTR containing the miR-218 binding sites.
Knockdown of Robo1 by siRNA in MKN28-M cells inhibited
cell invasion, which fell to levels similar to those observed after
transfection with the miR-218-expressing vector (Figure 5E and
5F). These observations suggest that miR-218 directly suppresses
Robo1-mediated cell invasion.
Figure 5. miR-218 targeted Robo1 by binding to its 39-UTR. (A)
The Robo1 39-UTR was a potential target of miR-218. (B and C) miR-218
and Robo1 levels were analyzed by qRT–PCR and western blot,
respectively. Robo1 levels decreased when miR-218 was upregulated
in response to the miR-218-expression vector in MKN28-M cells,
whereas the reverse was observed for Robo1 expression when miR-
218 was knocked down in MKN28-NM cells. (D) MKN28-M cells were co-
transfected with miR-218 and a luciferase reporter (Luc-Robo1)
containing a fragment of the Robo1 39-UTR harboring either the miR-
218 binding site or a mutant (Luc-Robo1-mu) in which the first six
nucleotides of the miR-218 binding site were deleted. A luciferase
reporter construct engineered with a non-related fragment of cDNA
was used as a negative control (Luc-control). The assays showed that
luciferase activity in the Luc-Robo1 group was significantly decreased
compared to the luciferase activity of the mutant and negative control
groups. (E) MKN28-M-miR-218 cells, which stably over-expressed miR-
218, were transiently transfected with a Robo1 expression construct or
a Robo1 mutant construct lacking the miR-218 binding site. MKN28-M
cells were transfected with Robo1 siRNA or a negative control siRNA.
Western blot analysis for Robo1 showed that co-transfection of miR-218
and the Robo1 mutant construct produced higher levels of Robo1
protein than co-transfection of miR-218 and the Robo1 construct.
Robo1 siRNA effectively reduced the amount Robo1 protein observed.
(F) The cell invasion assay indicated that Robo1 mutant constructs
could reverse the effect of miR-218-mediated suppression of cell
invasion. Knockdown of Robo1 by siRNA in MKN28-M cells inhibited cell
invasion. * P,0.05.
doi:10.1371/journal.pgen.1000879.g005
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the absence of miR-218, to promote GC invasion
Two types of miRNAs exist: intergenic and intronic. The
former are located in non-coding regions between genes, and their
corresponding pri-miRNAs are generally transcribed from their
own promoters by RNA polymerase II. The latter are located
within the introns of host genes, and their biogenesis is controlled
by the host gene promoters [41,42]. miR-218 is an intronic
miRNA. Two genes code for mature miR-218, miR-218-1 and
miR-218-2, which are located within intron 15 of Slit2 and intron
14 of Slit3, respectively (Figure 6A). The intronic location of the
two miR-218 genes prompted us to ask whether miR-218-1 and
miR-218-2 are transcribed together with their host gene mRNAs.
To test this hypothesis, we used qRT-PCR to examine the
expression of the miR-218-1 precursor, the miR-218-2 precursor,
mature miR-218, Slit2 mRNA, and Slit3 mRNA in the GC tissues
used in the survival analysis. Statistical analysis of the correlation
coefficient of the qRT-PCR results revealed a significant positive
correlation between the levels of Slit2 mRNA and miR-218-1 and
between the levels of Slit3 mRNA and miR-218-2 (Figure 6B and
6C). These results indicate that the miR-218 coding genes, miR-
218-1 and miR-218-2, are transcribed together with their host
genes, Slit2 and Slit3, respectively. A significant positive
correlation between the levels of miR-218 and miR-218-2
(Figure 6D) was seen in GC; however, no such correlation was
seen between the levels of miR-218 and miR-218-1 (Figure 6E).
These results indicate that downregulation of miR-218 in GC is
promoted by a decrease in miR-218-2, but not in miR-218-1.
Consistent with this conclusion, Slit3 expression was significantly
reduced in GC (222.4360.21, mean 6 SE) compared to normal
gastric tissue (220.7960.23, mean 6 SE), (P,0.0001, t=7.67,
paired t-test) (Figure 6F), whereas Slit2 expression was not
significantly different (P=0.0772, paired t-test) (Figure 6G). In
summary, our experimental results suggest that significant
upregulation of the Robo1 gene in response to removal of miR-
218 may induce a subsequent upregulation of the Slit-Robo1
pathway through its interaction with Slit2, facilitating tumor cell
migration and invasion.
Discussion
To study a disease, it is vital to construct an ideal model. In the
present study, we isolated invasive and non-invasive cell
subpopulations from established human GC cell lines using the
repeated transwell approach, which has been successfully applied
in many studies investigating tumor metastasis [43–48]. The
results of metastatic examination in vitro and in vivo showed that the
established cell sublines had distinct invasive and metastatic
capabilities. Here, we screened not only cell sublines derived from
GC cell lines with high-invasive potential, but also those with low-
invasive potential. With the exception of their metastatic abilities,
the selected cell sublines were both quite similar, since they share
the same genetic background. Since the major difference between
the two types of sublines is metastatic capability, the genes that
differ between them should correlate well with metastasis.
Moreover, our method is able to distinguish invasion stages from
metastasis and enables the study of specific steps in metastasis,
which cannot be assessed in the live-animal model.
Recently, miRNAs have been reported to promote [49,50] or
suppress [51–54] tumor metastasis, providing a new perspective on
the metastatic process. Nonetheless, the role of miRNAs in GC
metastasis is lacking. In this report, we explored and obtained for
the first time 45 metastasis-related miRNAs in GC based on a
well-established metastasis cell model. The finding that miR-218
was downregulated in metastatic GC is intriguing, as decreased
miR-218 levels have been reported in several types of solid tumors
[24–27,55], indicating that the loss of miR-218 may be a common
event in tumorigenesis. In the present study, we focused on the
effect of miR-218 on GC metastasis and demonstrated that miR-
218 acts as a tumor suppressor in GC metastasis. Restoration of
miR-218 reduced cell migration and invasion in vitro and tumor
metastasis in vivo. To obtain stable cell lines that over-expressed
miR-218, we transfected MKN28-M cells with miR-218 plasmids
and screened by G418. We selected twelve cell colonies in the
miR-218-transfected group and found 10 out of 12 colonies
exhibited remarkably uniform, stable and high-level expression of
miR-218. Furthermore, three randomly chosen monoclonal cell
Figure 6. Results of the expression analysis of miR-218, miR-
218-1, miR-218-2, Slit2, and Slit3 in 40 matched GC tumors and
corresponding normal tissues via qRT–PCR. (A) Schematic
representation of the miR-218 genomic locus hosted in the intron of
Slit. Expression patterns of Slit2 with miR-218-1 (B) and Slit3 with miR-
218-2 (C) exhibited a significant positive correlation, as did mature miR-
218 with the miR-218-2 precursor (D), but not with miR-218-1 (E), in GC.
A significant differential gene expression pattern was detected between
normal and tumor samples with regard to Slit3 (P,0.0001, paired
Student’s t-test, Figure 6F), but not Slit2 (P=0.0772, Figure 6G). Using
relative quantification methods, the results were expressed as –DCt. The
left and right lines of (F,G) represent the mean values for the normal
and tumor groups, respectively.
doi:10.1371/journal.pgen.1000879.g006
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plasmid transfection strategies often result in lower integration
efficiency compared to viral expression leading to the possibility of
stochastic selection of rare functionally heterogeneous variants
from the initial bulk population. Therefore the future use of viral
expression systems should create a more unbiased starting
population to test our hypothesis.
As part of our research on how the loss of miR-218 affects GC
metastasis, we demonstrated that Robo1 was a critical down-
stream target of miR-218. It is known that Robo is an axon
guidance receptor for Slit and is conserved in animals ranging
from fruit flies to mammals. In mammals, three Slit (Slit1–3) and
four Robo (Robo1–4) genes have been described [56,57]. The
Slit–Robo interactions convey signals mediating repulsive cues on
axons and growth cones during neural development and
participate in T cell and monocyte chemotaxis [58–64]. As for
other developmental pathways, aberrant expression of the Slit-
Robo genes has been observed in a variety of tumor types
[65–68]. For instance, in breast carcinoma tissue samples, Robo1
has been shown to be over-expressed, and it has been
demonstrated to induce migration of breast cancer cell lines
[37]. Slit2-Robo1 signaling facilitates glioma cell migration [36]
and is involved in angiogenesis by increasing microvessel density
and tumor mass in a tumor xenograft model [30]. Wang et al.
demonstrated that the over-expression of Robo1 in new blood
vessels in tumors induces cancer neovascularization and growth
via an interaction between Robo1 and its ligand, Slit2. They also
identified phosphoinositide-3-kinase (PI-3K) as a downstream
effector of Slit2/Robo1 signaling. This suggests that there exists a
Slit–Robo1–PI-3K cascade that could lead to the generation of
phosphoinositol-3,4,5-triphosphate and the subsequent activation
of small GTPases that mediate cell movement and remodeling of
the actin cytoskeleton [30,35]. In contrast, other studies have
argued that the downregulation of Robo1 caused by deletions or
epigenetic modifications may play a role in tumor progression
[69–73]. We propose that a tissue-specific expression pattern
exists for the Slit-Robo genes.
In the current study, we found that Robo1 was often expressed
at high levels in invasive cells and at low levels in non-invasive
cells, whereas miR-218 displayed the opposite expression pattern.
When we transfected the miR-218-expression vector and inhib-
iting oligonucleotides into MKN28-M and MKN28-NM cells,
respectively, an inverse expression pattern was observed between
miR-218 and Robo1, that is, if miR-218 expression was high,
Robo1 expression was low and vice versa. This result was further
confirmed in clinical samples and in luciferase activity assays. We
also noticed that induction of expression of Robo1 by the Robo1
mutant construct without the miR-218 binding site could reverse
miR-218-mediated suppression of tumor cell invasion. In contrast,
knockdown of Robo1 gene expression by RNAi had an effect on
reducing tumor cell invasion similar to that of the restoration of
miR-218, although Robo1 knockdown alone demonstrated a weak
effect. This could be because Robo1 is not the only target of miR-
218 that is relevant to tumor metastasis. These findings indicate
that the invasion suppression effect of miR-218 is at least partly
mediated through a decrease in Robo1 expression. This is also the
first study to show that the tumor-associated gene Robo1 is
negatively regulated by miR-218 via a specific target site (nt 971–
978) within the 39-UTR. The Robo1 receptor is crucial for the
response to extracellular signals and cellular phenotypic changes;
therefore, tight regulation of the Robo1 receptor by miR-218 may
facilitate more robust signal transduction. Anti-Robo1 monoclonal
antibody has been reported to be an effective treatment for
Robo1-expressing cancers [30,33]. In the present study, we found
a new inhibitor of Robo1, miR-218, that may potentially be used
to treat some types of cancer.
As mentioned above, Slit1, Slit2, and Slit3 comprise the Slit
family of proteins. Although the genes overlap, their expression
patterns and functions are distinct. The former two proteins are
known to be involved in axon guidance and cell migration [37,74],
while Slit3 is involved in the development of organs and organ
systems, including the diaphragm and the kidney [75]. In
agreement with these data, we found that Slit2, but not Slit3,
interacted with Robo1 to promote GC invasion.
In addition, we demonstrated that the miR-218 coding genes
were located in and transcribed together with Slit genes, which
were Robo1 ligands, thus creating a negative feedback loop that
regulates Slit/Robo1 signaling. Sailen Barik demonstrated that an
intronic miRNA, miR-338, silenced genes that are functionally
antagonistic to its host gene product, thus creating a positive
feedback loop that assists in the physiological role of the host gene
[76]. However, a miRNA hosted in a ligand gene that
simultaneously targets its corresponding receptor gene has never
been reported. We have identified a negative regulatory loop
involving the ligand (host gene), the intronic miRNA, and the
receptor, in which the miRNA is co-transcribed with the ligand
while receptor expression is repressed. The associations among
ligand/receptor and intronic miRNA indicate that the early steps
in the information flow may have built-in controls to limit excess
signal propagation, which include a negative feedback loop to
preserve homeostasis. This regulatory model, which is based on
intronic miRNAs, is a novel mechanism of regulation in receptor
signaling systems. Even though the full regulatory circuitry of miR-
218 has yet to be completely elucidated, our study revealed a
potential negative feedback pattern in which a miRNA was co-
transcribed with the Slits ligand and repressed Robo1 receptor
expression. This study not only provides new insights into the
metastatic mechanism of GC but also generates a set of testable
hypotheses that are helpful for understanding the miRNA-
mediated regulation of cellular ligand/receptor interactions.
In conclusion, we have identified miRNAs that are aberrantly
expressed in invasive GC cells compared with non-invasive GC
cells. Here we have showed that when significantly downregulated,
miR-218 promoted GC cell invasion and metastasis, at least in
part via induction of Robo1. This result indicates that restoration
of miR-218 may be a rational therapeutic strategy for the
treatment of GC in the future. It remains to be investigated
whether the other differentially expressed miRNAs found in this
study also participate in GC metastasis. Importantly, our findings
have implications for describing new mechanisms for miRNA-
mediated regulation of receptor signaling.
Materials and Methods
Ethics statement
All experimental procedures were approved by the Institutional
Review Board of the Fourth Military Medical University. Written
informed consent was obtained for all patient samples. Animal
experiments were performed with the approval of the Institutional
Committee for Animal Research and in conformity with national
guidelines for the care and use of laboratory animals.
Cell culture
The human GC cell lines MKN28 and SGC7901 were
routinely maintained in RPMI-1640 medium (GIBCO, Carlsbad,
CA, USA) supplemented with 10% fetal bovine serum, 100 U/ml
of penicillin sodium, and 100 mg/ml of streptomycin sulfate at
37uC in a humidified air atmosphere containing 5% carbon
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logarithmic phase of growth.
Isolation of invasive and non-invasive cell sublines using
transwell chambers
Six-well polycarbonate transwell membrane inserts with 8-mm
pores (Corning, USA) were used to isolate cell sublines with
different levels of invasiveness from the cultured MKN28 cell line.
First, cells that were serum-starved for 24 h were suspended in
serum-free RPMI-1640 to a final cell density of 5610
5 cells/mL.
A 1 mL cell suspension was seeded into the top chamber, which
was coated with 200 mg/mL of Matrigel (BD Biosciences, San
Jose, CA, USA), and the lower well beneath the polycarbonate
membranes was filled with 2.5 mL RPMI-1640 medium supple-
mented with 20% bovine serum to create a chemotactic gradient
to stimulate penetration of the cells. Following incubation for 24 h
at 37uC, the invasive cells on the underside of the membrane and
the non-invasive cells on the top of the membrane were harvested
aseptically and were expanded for selection. Via ten-round
selection, the cell subline that failed to invade through the
membranes in all selection rounds was designated as MKN28-
NM, and the subline that was able to migrate through the
membranes was designated as MKN28-M. We also obtained two
cell sublines, SGC7901-M and SGC7901-NM, derived from the
SGC7901 GC cell line, using the same method (Figure 1).
In vitro migration and invasion assays
A 24-well transwell plate (8-mm pore size, Corning, USA) was
used to measure each cell line’s migratory and invasive ability. For
transwell migration assays, 2.5610
4 cells were plated in the top
chamber lined with a non-coated membrane. For invasion assays,
chamber inserts were coated with 200 mg/mL of Matrigel and
dried overnight under sterile conditions. Then, 5610
4 cells were
plated in the top chamber. In both assays, cells were suspended in
medium without serum or growth factors, and medium supple-
mented with serum was used as a chemoattractant in the lower
chamber. After incubation at 37uC for 24 h, the top chambers
were wiped with cotton wool to remove the non-migratory or non-
invasive cells. The invading cells on the underside of the
membrane were fixed in 100% methanol for 10 min, air-dried,
stained in 0.1% crystal violet, and counted under a microscope.
The mean of triplicate assays for each experimental condition was
used.
Experimental metastasis
To produce experimental metastasis, cells were washed and
resuspended in PBS. Five-week-old BALB/C-nu/nu nude mice
obtained from the Shanghai Laboratory Animal Center of China
were injected into the lateral tail vein, and the animals were
maintained in a sterile animal facility. Each tumor cell subline was
injected into ten mice. After ten weeks, the mice were killed, and
the lungs and liver were examined for metastases. Tumor tissues
derived from various organs were dissected and examined
histologically. The experiments were repeated two to three times.
miRNA microarrays
Total RNA was extracted from each cell subline using the
miRVana miRNA Isolation Kit (Ambion Inc., Austin, TX, USA)
according to the manufacturer’s instructions. The purity and
quantity of the isolated RNAs were assessed using 1% formalde-
hyde-agarose gel electrophoresis and spectrophotometry (Bio-Rad,
Hercules, CA, USA). We then submitted the samples to
KangChen-Biotech (Shanghai, China) for array hybridization on
a miRCURY LNA microRNA array (v.10.0, Exiqon, Vedbaek,
Denmark). Each microarray chip was hybridized with a single
sample labeled with either Cy3 or Cy5. Background subtraction
and normalization were performed. We selected miRNAs whose
expression levels between invasive cell sublines and non-invasive
cell sublines differed by at least 1.5-fold.
Clinical samples
Forty patients (30 males and 10 females) who had undergone
gastrectomy with lymph node dissection for gastric carcinoma at
Xijing Hospital between March and September of 2003 were
included in the study (Table S2). The patients ranged in age from
26 to 77 years (median 54.13 years). None of the patients received
preoperative chemotherapy. The resected specimens were histo-
logically examined by H&E staining. The primary tumor tissues
and corresponding non-tumor mucosa and lymph nodes were
collected from each patient immediately after surgical removal and
snap-frozen in liquid nitrogen until further use. Total RNA from
the frozen tissues was isolated with Trizol (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instructions.
Quantitative real-time RT–PCR (qRT–PCR)
Total RNA was extracted with suitable reagents. The TaqMan
stem-loop RT-PCR method was used to assess the expression of
miRNAs with kits from Applied Biosystems (Foster City, CA,
USA). SYBR green real-time RT-PCR was performed to detect
Slit2, Slit3, and Robo1. All RT-PCR experiments were performed
on a Chromo4 Real-Time PCR Detection System (Bio-Rad,
Hercules, CA, USA). The primers for miR-218 and its precursors
were obtained from Applied Biosystems(Foster City, California,
USA)and Eurogentec North America, Inc (Flintkote Avenue, San
Diego, California, USA), respectively. The primers for Slit2, Slit3,
and Robo1 were designed to produce amplicons that were
76–150 bp in length and with an annealing temperature of
approximately 60uC using Primer Premier v5.0 Software. Data
are presented as fold differences relative to either 18S for Slit2,
Slit3, and Robo1 or U6 for miRNA based on calculations of
2
2DDCt. All primer sequences in this study are listed in Table
S3.
Construct design and cell transfections
miR-218-expressing vector. The precursor sequence of
miR-218 (110 bp, MI0000295) generated by annealing and
primer extension with miR-218-precursor-F and miR-218-
precursor-R (Table S3) was digested with BamHI and HindIII
and cloned into the BamHI-HindIII fragment of the pGenesil-1
vector. A construct including the nonspecific miRNA cel-miR-67
(99 bp, MI0000038) was used as a negative control.
Luc-Robo1 vector. The Robo1 39-UTR containing the
predicted miR-218 binding site was amplified by RT-PCR from
the total RNA of cultured MKN28 cells and was cloned into the
pCR2.1-TOPO vector (Invitrogen, Carlsbad, CA, USA). The
pCR2.1-TOPO-Robo1 39-UTR construct was digested with SpeI
and HindIII. The resulting fragment was subcloned into the SpeI
and HindIII sites of the pMIR-REPORT miRNA expression
reporter vector (Applied Biosystems). The first six nucleotides
complementary to the miR-218 seed-region were deleted from the
mutant constructs using the QuikChange Site-Directed
Mutagenesis Kit (Stratagene) according to the manufacturer’s
protocol.
Robo1-expressing vector with or without miR-218 binding
sites. Full-length Robo1 cDNA that entirely lacks the 39-UTR
(Clone ID: 9057080) was purchased from Open Biosystems (USA)
and was subcloned into the eukaryotic expression vector
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Robo1-expressing vector was constructed by inserting the
fragment of the predicted miR-218 binding site into the Robo1
mutant expression vector. Robo1 siRNA and negative control
oligonucleotides were purchased from GenePharma (Shanghai,
China).
Cell transfections. MKN28-M cells were transfected with
the miR-218-expressing vector or the control vector expressing a
nonspecific miRNA, cel-miR-67, using Lipofectamine 2000
(Invitrogen), and were selected with 400 mg/L G418 to generate
two stable monoclonal cell lines (a miR-218 stable cell line,
MKN28-M-miR-218, and a control stable cell line, MKN28-M-
miR-control). The oligonucleotides comprising the miR-218
inhibitor and the mismatched sequence negative control were
purchased from Ambion Inc. and were transfected into MKN28-
NM cells using Oligofectamine (Invitrogen). The Robo1-
expressing vector with or without the miR-218 binding sites was
transfected into MKN28-M-miR-218 cells, and Robo1 siRNA was
transfected into MKN28-M cells.
Luciferase assay. The pMIR-REPORT b-galactosidase
control vector and Luc-Robo1, Luc-Robo1-mu, or Luc-control
were co-transfected into MKN28-M-miR-218 cells. Lysates were
prepared at 48 h post-transfection. Luciferase activity was
measured using the Dual-Light luminescent reporter gene assay
(Applied Biosystems). All measurements were normalized to b-
galactosidase activities to correct for variations in transfection
efficiencies and for non-miR-218-specific effects of miRNA
transfection on enzymatic activity.
Western blot. Cellular proteins were extracted and separated
in SDS-PAGE gels, and western blot analyses were performed
according to standard procedures. Western blotting of b-actin on
the same membrane was used as a loading control. The antibodies
used were anti-Robo1 (SC-25672) and anti-b-actin (sc-47778),
both from Santa Cruz Biotechnology (CA, USA).
Statistical analyses. All data are presented as means 6 SE
and were analyzed using Prism 5.0 software (GraphPad). The
significance of the observed differences was determined with the
Student’s t-test or the x2 test. The relationships among the miR-
218-1 precursor, the miR-218-2 precursor, mature miR-218, Slit2
mRNA, and Slit3 mRNA were analyzed by correlation coefficients
and linear regression analysis. P,0.05 was considered statistically
significant. * P,0.05; ** P,0.01.
Supporting Information
Figure S1 No significant difference in the proliferation rate
was observed in the three cell sublines. (A) Proliferation rates of
the cell sublines were detected by the MTT assay. (B) Tumor
volume growth curves for each cell subline are shown. Tumor
sizes were measured using calipers. Tumor volume was
calculated using the formula (length 6width
2)/2. (n=5,paired
Wilcoxon test, P.0.05). (C) On day 37, all tumors were
collected to measure tumor weights (P.0.05; n=5).(D)Photos
of tumors 37 days after injection with MKN28, MKN28-NM, or
MKN28-M cells.
Found at: doi:10.1371/journal.pgen.1000879.s001 (6.14 MB TIF)
Figure S2 Cell-cycle analysis of three established cell sublines.
(A) Representative flow cytometry results for each cell subline. (B)
Cell-cycle distribution (P.0.05; n=3).
Found at: doi:10.1371/journal.pgen.1000879.s002 (2.82 MB TIF)
Figure S3 qRT-PCR analysis of the relative expression of miR-
218 and Robo1. (A) Expression of miR-218 and Robo1 were
reversed in invasive (MKN28-M and SGC7901-M) and non-
invasive GC cells (MKN28-NM and SGC7901-NM) compared
with GES cells. (B) Robo1 mRNA levels decreased when miR-218
was upregulated in response to transfection of MKN28-M cells
with miR-218-expressing vector.
Found at: doi:10.1371/journal.pgen.1000879.s003 (2.56 MB TIF)
Figure S4 Immunohistochemical analysis of Robo1. (A-F)
represent normal and tumor tissues taken from the same patient
and processed in the same way using paraffin sectioning. (A,C,E)
H&E staining of normal gastric mucosa, primary gastric cancer,
and the ovarian metastasis from gastric cancer. Magnification,
1006. (B,D,F) Robo1 in normal gastric mucosa, primary gastric
cancer, and ovarian metastasis from gastric cancer (serial section
adjacent to the H&E-stained specimen). Magnification, 1006.
Robo1 was expressed at low levels in the gastric epithelial cells of
normal tissues and was expressed at increased levels in gastric
cancer tissues, especially in metastatic tumor tissues.
Found at: doi:10.1371/journal.pgen.1000879.s004 (9.91 MB
TIF)
Figure S5 miR-218 has the ability to specifically suppress
metastasis without affecting cell proliferation. (A) MTT assay of
the effects of miR-218 on proliferation of MKN28-M cells. No
significant difference in the proliferation rate was found between
MKN28-M-miR-218 cells stably over-expressing miR-218 and
control cells. (B) MKN28-M-miR-218 and control cells were
subcutaneously injected into nude mice. Growth curves of primary
gastric cancers formed by MKN28-M-miR-218 cells or control
cells are shown. Tumor sizes were measured using calipers. Tumor
volume was calculated using the formula (length 6 width
2)/2.
Each data point represents the mean 6 standard error (n=10;
P.0.05). (C) Median tumor weight at day 72. Data are presented
as mean 6 standard error (n=10; P.0.05). (D) Cell cycle
distribution (P.0.05; n=3). (E) Representative H&E staining of
lungs and livers isolated from mice that received injections of
MKN28-M-miR-control or MKN28-M-miR-218 cells. Magnifi-
cation, 2006.
Found at: doi:10.1371/journal.pgen.1000879.s005 (3.55 MB TIF)
Table S1 Differentially expressed miRNAs in highly invasive
GC cells versus non-invasive GC cells.
Found at: doi:10.1371/journal.pgen.1000879.s006 (0.10 MB
DOC)
Table S2 Clinicopathologic features in 40 tumor samples.
Found at: doi:10.1371/journal.pgen.1000879.s007 (0.25 MB
DOC)
Table S3 Primer sequences used in the study.
Found at: doi:10.1371/journal.pgen.1000879.s008 (0.04 MB
DOC)
Text S1 Supplementary methods.
Found at: doi:10.1371/journal.pgen.1000879.s009 (0.05 MB
DOC)
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